All News
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
Read Article
EULAR 2021 – Day 2 Report
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlights from Day 2.
Read Article
HOT🔥: thermography of hands in IA remotely collected via smartphone correlates w/ US features 0.48, p<0.01 and SJC 0.48, p<0.01), DAS28 (0.73, p<0.01), CDAI (0.84, p<0.01) and SDAI (0.82, p<0.01). A future tool for patients remote follow-up?
#OP0300 @Rheumnow #EULAR2021 https://t.co/MJLpz6eqIy
Aurelie Najm AurelieRheumo ( View Tweet)
Just a reminder: RA-ILD doesn't just happen in early disease; risk continues on long after diagnosis.
PS don't smoke if you have RA; smokers have an adj HR 1.92
PPS don't smoke if you don't want to get RA
PPPS don't smoke.
@MayoClinic POS0210 #EULAR2021 @RheumNow https://t.co/elhvJrK7B4
David Liew drdavidliew ( View Tweet)
Which RA pts have high HAQ? F/U of 2 ERA cohorts [NOAR 1001 pts, #ESPOIR 767 pts] compared pts with high vs lower HAQ. DAS28 was = in 2 groups! But high HAQ occurred in older, females &⬆️fatigue OP0183 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari >Adalimumab for pain, HAQ, am stiffness but = on fatigue. POS0649 @RheumNow @eular_org #EULAR2021
Janet Pope Janetbirdope ( View Tweet)
Who responds better to bDMARDs in RA, PsA & SpA? Men, women or equal? POS0208 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Lots of discussion about RA-ILD, but what about bronchiectasis (BR) in RA? We found a pooled prevalence of RA-BR of 18.7% (some may have been subclinical). POS0522 Prevalence of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis #EULAR2021 @Janetbirdope
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Janet Pope Janetbirdope ( View Tweet)
Lower ILD incidence in PsA than RA in a large Nordic registry
⭐️ No significant ⬆️ in ILD in those using MTX
Abs#OP0222
#EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6
Robert B Chao, MD doctorRBC ( View Tweet)
Disappointed to have missed lots of interesting sessions at Day 3 #EULAR2021 but look forward to catching up, starting with the difficult-to-treat #rheumatoidarthritis session! I particularly like this helpful summary on complexities & factors to consider in patients with D2T RA. https://t.co/H8n9Q2QNDW
Mrinalini Dey DrMiniDey ( View Tweet)
Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Beamed in & out of talk like #StarTrek @eular_org @RheumNow https://t.co/y4qToeFKE7
Janet Pope Janetbirdope ( View Tweet)
#Polypharmacy of meds not related to RA ⬇️remission & more adverse events but not if adjusting for comorbidities- so many diagnoses with RA ⬇️outcomes only defined as >1 drug #EULAR2021 @RheumNow OP0098 https://t.co/lMazBDTPw1
Janet Pope Janetbirdope ( View Tweet)
A Triple Header of RA Plenary Abstracts: Dr. Jonathan Kay #EULAR2021
Dr. Jonathan Kay reviews three RA abstracts from the opening plenary session at the EULAR 2021 virtual meeting: abstract OP0012; abstract OP0007; and abstract OP0006.
https://t.co/6GhSLXqysd https://t.co/h2k00GzHE5
Links:
Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA pts cycle through more advanced therapies! Kind of obvious but in N=363, 9.4% with advanced Rx were difficult to treat vs 39% if > 1 ts\bDMARDs. Worse pts had ⬆️disease duration. Drug resistance over time? POS0405 @RheumNow #EULAR2021 @eular_org
Janet Pope Janetbirdope ( View Tweet)
Stop #smoking!
Smoking is not good for you & others!
👉🏽Passive smoking exposures during childhood & adulthood associated with increased risk of #RheumatoidArthritis
Could favour citrullination in genetically proned people
By @YannNgyn OP0012 #EULAR2021
#rheumatoid https://t.co/ImDR0aLAXd
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy in 320 Rxs in 215 pts JAKi lasted longer adjusting for age, sex, RA duration & line of therpy & 1st line Rx POS0205 #EULAR2021 @RheumNow https://t.co/4m2RXBkTDr
Janet Pope Janetbirdope ( View Tweet)
JAKi to #JAKi cycling is common in #rheumatoidarthritis Rx. Opal registry >53000 pts, 1/4 treated with JAKi (4000) & 44% new starts were Jaki. JAKi to JAKi cycling was >40%! POS0223 #EULAR2021 @RheumNow https://t.co/XV7wVJsE9c
Janet Pope Janetbirdope ( View Tweet)
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021
https://t.co/S0ownscRKv https://t.co/PJODe0U6wr
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Hellgren on pregnancy outcomes in RA 📈disease activity assoc preterm birth and small gestational age. Low disease activity = no increased risk compared controls @RheumNow #EULAR2021 Abstr#OP0210 https://t.co/L26xWhIFv6
Richard Conway RichardPAConway ( View Tweet)
